alleen voor onderzoeksdoeleinden

PD 98059 MEK remmer

Name: PD 98059
Brand: Selleck Chemicals
SKU: S1177
Rating: 5 (518 reviews)

Cat.nr.S1177

PD98059 is een niet-ATP-competitieve MEK-remmer met een IC50 van 2 μM in een celvrije test, remt specifiek de MEK-1-gemedieerde activering van MAPK; remt ERK1 of ERK2 niet direct. PD98059 is een ligand voor de arylhydrocarbonreceptor (AHR) en functioneert als een AHR-antagonist.

Chemische structuur

Molecuulgewicht: 267.28

Spring naar

Kwaliteitscontrole

Batch: Zuiverheid: 99.92%

99.92

Gerelateerde doelwitten	ERK p38 MAPK Raf JNK Ras KRas S6 Kinase MAP4K TAK1 Mixed Lineage Kinase
Overig MEK Inhibitoren	PD0325901 (Mirdametinib) U0126-EtOH PD184352 (CI-1040) BIX 02189 Pimasertib (AS-703026) Refametinib (RDEA119) TAK-733 AZD8330 SL-327 BIX 02188

Celkweek, behandeling & werkzame concentratie

Cellijnen	Assaytype	Concentratie	Incubatietijd	Formulering	Activiteitsbeschrijving	PMID
TE4	Function Assay	50 μM	48 h	DMSO	upregulates the expression of HLA class I	24244023
MKN7	Function Assay	50 μM	48 h	DMSO	increases expression of HLA-A02 or HLA-A24 molecules	24244023
OE19	Function Assay	50 μM	48 h	DMSO	increases expression of HLA-A02 or HLA-A24 molecules	24244023
NCI-N87	Function Assay	50 μM	48 h	DMSO	increases expression of HLA-A02 or HLA-A24 molecules	24244023
KATOIII	Function Assay	50 μM	48 h	DMSO	increases expression of HLA-A02 or HLA-A24 molecules	24244023
NUGC3	Function Assay	50 μM	48 h	DMSO	increases expression of HLA-A02 or HLA-A24 molecules	24244023
NUGC2	Function Assay	50 μM	48 h	DMSO	increases expression of HLA-A02 or HLA-A24 molecules	24244023
SGC-7901	Apoptosis Assay	20 μM	24 h		inhibits CP-mediated apoptosis	24241351
MG-63	Function Assay	20 μM	0.5 h		blocks the CH-induced phosphorylated ELK1 protein expression	24239640
ARPE-19	Function Assay	20 μM	0.5 h		inhibits Apelin-induced phosphorylation of Erk and Akt	24227918
CRL-2302	Function Assay	20 μM	0.5 h		inhibits Apelin-induced phosphorylation of Erk and Akt	24227918
MCF-7	Apoptosis Assay	20 μM	1 h		increases caspase-9 enzyme activity	24216289
MCF-7	Function Assay	20 μM	1 h		abolishes expression of phosphorylated ERK co-treatment with conjugate	24216289
7402	Apoptosis Assay	30 μM	5 d		decreases cell proliferation	24211253
HT-29	Function Assay	20 μM	48 h		reduces the BNIP3 expression pre-treated with 5-aza-dC	24211581
DLD-1	Function Assay	20 μM	48 h		reduces the BNIP3 expression pre-treated with 5-aza-dC	24211581
7721	Apoptosis Assay	30 μM	5 d		decreases cell proliferation	24211253
SGC7901	Apoptosis Assay	50 μM	24/48/72 h	DMSO	induces apoptosis combined with JAK2 shRNA	24178240
SMMC7721	Function Assay	25/50 μM	24 h		suppresses the expression of p-Akt or p-ERK1/2	24168056
MCF-7	Growth Inhibition Assay	10 μM	48h	DMSO	reverses BNF-induced cell cycle arrest	24163404
Caco-2	Function Assay	50 μM	48h	DMSO	enhances the mRNA levels of SCNN1A,FXYD3, LCT, LOX, HIF3A, ZG16, PDE6A and LGALS16 genes co-treated with Dex	24161695
HAECs	Function Assay	10 μM	1 h		attenuates TNF-α-stimulated ICAM-1 and VCAM-1 expression	24134657
Ca9-22	Function Assay	3 μM	1 h		abolishes the ability of HbR to induce IL-8 production	24126532
Ca9-22	Function Assay	3 μM	1/2 h		reduces HbR-induced ATF-2 phosphorylation	24126532
AGS	Function Assay	10 μM	0.5 h		inhibits the upregulation of the IL-8 gene	24106166
Caco-2	Apoptosis Assay	10 μM	24 h		decreases cell apoptosis induced by 5-FU	24095863
A549	Function Assay	50 μM	2 h		blocks ERK phosphorylation mediated by 1,2-NQ	24067727
HPMC	Function Assay	10 μM	48 h		reverses the changes in cell morphology induced by HGPDS	24042838
HCT-8	Apoptosis Assay	10 μM	24 h		decreases cell apoptosis induced by 5-FU	24095863
HPMC	Apoptosis Assay	10 μM	24 h		reverses decrease in cell viability induced by HGPDS	24042838
MGC803	Apoptosis Assay	20 μM	1 h		inhibits apoptosis induced by IFN-α and 5′-DFUR	24027750
SGC7901	Apoptosis Assay	20 μM	1 h		inhibits apoptosis induced by IFN-α and 5′-DFUR	24027750
G292	Apoptosis Assay	30 μM	2 h		restores capsaicin-induced cell death	24012930
COLO205	Apoptosis Assay	10/20/40 μM	24 h		induces DNA ladder formation	24019108
BxPC-3	Function Assay	10 μM	6 h		increase miR-143 expression	23973710
HPAF-II	Function Assay	10 μM	6 h		increase miR-143 expression	23973710
HepG2	Function Assay	40 μM	6/12 h		inhibits the increase of p-ERK1 and p-c-Jun protein expression by PL	23942851
HL-60	Apoptosis Assay	50 μM	1 h		rescues BA145 mediated apoptosis	23948751
LNCaP	Function Assay	10 μM	1 h		decreases the EGF upregulated p-YB-1	23838318
HUVECs	Function Assay	25 μM	1 h		increase NF-κB p65 nuclear translocation	23901008
HL60	Function Assay	20 μM	72 h	DMSO	inhibits -induced CD11b expression	23825585
NB4	Function Assay	10 μM	72 h	DMSO	inhibits -induced CD11b expression	23825585
EPOR/CR3	Function Assay	50 μM	3 h		reduces EPO and/or IL-3-induced the tyrosine phosphorylation	23820731
HUASMCs	Function Assay	10 μM	24 h		inhibits Ang II-induced ERK1/2 phosphorylation level	23816468
HUASMCs	Function Assay	10 μM	24 h		diminishes Ang II-caused SOCS3 mRNA and protein expression	23816468
SGC7901	Function Assay	10 μM	24 h		inhibits the expression of phosphorylated ERK1/2	23792588
MKN45	Growth Inhibition Assay	10 μM	24/48/72 h		inhibits cell growth co-treated with DAPT	23792588
SGC7901	Growth Inhibition Assay	10 μM	24/48/72 h		inhibits cell growth co-treated with DAPT	23792588
MKN45	Function Assay	10 μM	24 h		inhibits the expression of phosphorylated ERK1/2	23792588
SGC7901	Apoptosis Assay	10 μM	24 h		increases the DAPT-induced cell apoptosis	23792588
MKN45	Apoptosis Assay	10 μM	24 h		increases the DAPT-induced cell apoptosis	23792588
BxPC-3 cells	Growth Inhibition Assay	20 μM	0.5 h		inhibits VEGF-A-regulated HUVEC growth and tube formation induced by PAR-2 AP	23764046
NB4	Apoptosis Assay	10/20/60 μM	1.5 h	DMSO	decreases cell viability co-treated	23735541
HepG2	Function Assay	20 μM	24 h		inhibits the HO-1 protein expression co-treated	23707609
HUVECs	Apoptosis Assay	2/4 μM	24/48 h		induces cell death	23707520
KG-1	Apoptosis Assay	20 μM	12 h		enhances cell apoptosis induced by S1	23706691
AML 1#	Apoptosis Assay	20 μM	12 h		enhances cell apoptosis induced by S1	23706691
A2780	Function Assay	20 μM	1 h		blocks DTCD-induced DR5 expression	23696862
KYSE30	Function Assay	50 μM	48 h	DMSO	upregulates the expression of HLA class I	24244023
TE5	Function Assay	50 μM	48 h	DMSO	upregulates the expression of HLA class I	24244023
TE1	Function Assay	50 μM	48 h	DMSO	upregulates the expression of HLA class I	24244023
TE3	Function Assay	50 μM	48 h	DMSO	upregulates the expression of HLA class I	24244023
KYSE30	Function Assay	20/50/100 μM	48 h	DMSO	inhibits p-Erk and wortmannin downregulated p-Akt in a dose-dependent manner	24244023
TE1	Function Assay	20/50/100 μM	48 h	DMSO	inhibits p-Erk and wortmannin downregulated p-Akt in a dose-dependent manner	24244023
TE4	Function Assay	20/50/100 μM	48 h	DMSO	inhibits p-Erk and wortmannin downregulated p-Akt in a dose-dependent manner	24244023
HT29	Function Assay	10 μM	2 h		inhibits of JAK2, ERK1/2 and STAT3 phosphorylation	24265293
HepG2	Apoptosis Assay	20 μM	24 h		inhibits ERK1/2 phosphorylation and enhances VB1-induced apoptosis	24247909
HepG2	Function Assay	20 μM	2 h		enhances VB1-induced FOXO3a transcriptional activity	24247909
MC-3	Apoptosis Assay	10 μM	24 h		potentiated MESC-induced apoptosis in cells	24270523
Raji	Function Assay	10 μM	1 h		blocks hsBAFF induced Erk1/2 phosphorylation	24269630
Raji	Growth Inhibition Assay	10 μM	1 h		inhibits the basal or hsBAFF-stimulated cell proliferation and viability	24269630
A549	Function Assay	30 μM	0.5 h	DMSO	inhibits thrombin-induced C/EBPβ Thr235 phosphorylation	24277696
HCSMCs	Growth Inhibition Assay	10 μM	24 h		blocks FABP4-induced HCASMC proliferation	24312381
PANC-1	Function Assay	20 μM	48 h		inhibits the expression of Δ6D in response to the PPARδ agonist	24294133
A549	Function Assay	30 μM	0.5 h	DMSO	inhibits the thrombin-induced IL-8/CXCL8-Luc activity	24277696
SW480	Function Assay	10 μM	20 h	DMSO	suppresses the CRT activity	24324366
HEK 293	Function Assay	10 μM	5 h	DMSO	inhibits Wnt-induced β-catenin/TCF4 activity and nuclear β-catenin accumulation	24324366
HEK 293	Function Assay	10 μM	5 h	DMSO	suppresses the CRT activity	24324366
HL-60	Function Assay	10/20 μM	1 h		inhibits the N. chinensisextract induced differentiation into granulocytes	24357020
HL-60	Function Assay	2 µM	16 h	DMSO	inhibits the association of pS621 Raf-1 and NFATc3, and the RA-induced phosphorylation of nuclear NFATc3	24330068
HeLa	Function Assay	50 μM	0.5 h		blocks TRX-1 nuclear migration and TXNIP down-regulation	24376827
HUVECs	Function Assay	10 μM	1 h		inhibits the HDL reduced COX-2 expression and PGI-2 release	24385109
MCF-7	Function Assay	10 μM	10/30 min		reduces the UTP-dependent ERK phosphorylation	24390819
HGC-27	Apoptosis Assay	1 µM	1 h		suppresses RAD001 plus MK-2206-induced cell viability loss	24416349
PC3	Apoptosis Assay	50 μM	0.5 h		inhibits MHY-449-induced apoptosis	24424889
HPAEpiCs	Function Assay	30 μM	1 h		inhibits TNF-α stimulated p42/p44 MAPK phosphorylation	24441870
BeWo	Function Assay	10 μM	2 h		inhibits ERK1/2	24433846
A498	Apoptosis Assay	50 μM	24 h		potentiates the pro-apoptotic effects of NC	24508476
NHBE	Function Assay	2/20 μM	2 h		attenuates IL-33 stimulated CXCL8/IL-8 secretion	24479526
A375	Cell Invasion Assay	10–20 µM	24 h		reduces melanoma cell invasion	24466036
HBMEC	Function Assay	10 μM	1 h		blocks VEGF-induced EphA2 expression	24458982
HCT-15	Function Assay		1 h		attenuates PGE2-induced phosphorylation of Erk	25431425
HCT-15	Apoptosis Assay		1 h		abolishes the protective effects of PGE2 against curcumin-induced apoptosis	25431425
786-O	Apoptosis Assay	50 μM	24 h		potentiates the pro-apoptotic effects of NC	24508476
HepG2	Growth Inhibition Assay	20 μM	24 h		suppresses TGF-β1-induced cell proliferation and invasion	25560488
SW480	Function Assay	20 μM	1 h		reduces the expression of ATF3 protein	25447816
MDA-MB-231	Function Assay	25 μM	2-3 h		decreases p-ERK1/2 and S100A4 expression	25555875
HepG2	Function Assay	10 μM	5 h		blocks phosphorylated MAPKs induced by exogenous TGF-β1	25560488
MCF-7	Function Assay	10 μM	1 h		inhibits IL-18-enhanced cell migration	25727011
H1355	Function Assay	25 μM	1 h		blunts the B[a]P-induced increase in phospho-Chk1 and phospho-ERK expression	25769181
PC12	Function assay				Inhibition of nerve growth factor-mediated MAP kinase activity in human PC12 cells, IC50 = 2 μM.	18077363
HT-29	Antiproliferative assay		5 days		Antiproliferative activity against human HT-29 cells after 5 days by WST1 assay, IC50 = 4 μM.	25078316
IEC6	Function assay		5 mins		Inhibition of MEK1/2 in rat IEC6 cells assessed as reduction in ERK1/2 loop phosphorylation dosed 30 mins before to stimulation with 10% serum for 5 mins by immunoblotting method, IC50 = 4.2 μM.	25078316
NG 108-15	Function assay				Concentration required to abolish MAPK activity in mouse neuroblastoma and rat glioma hybrid NG 108-15 cells, Activity = 10 μM.	15537354
PC12	Function assay	10 uM	5 hrs		Activation of Nrf2/ARE in rat PC12 cells assessed as HO-1 protein induction at 10 uM after 5 hrs pretreated with JNK inhibitor SP600125 for 1 hr before compound addition by Western blot analysis	21345685
PC12	Function assay	10 uM	5 hrs		Activation of Nrf2/ARE in rat PC12 cells assessed as HO-1 protein induction at 10 uM after 5 hrs pretreated with MEK2 inhibitor U0126 for 1 hr before compound addition by Western blot analysis	21345685
PC12	Function assay	10 uM	5 hrs		Activation of Nrf2/ARE in rat PC12 cells assessed as HO-1 protein induction at 10 uM after 5 hrs pretreated with MEK1 inhibitor PD98059 for 1 hr before compound addition by Western blot analysis	21345685
HeLa	Function assay	20 uM	3 hrs		Inhibition of ERK1/2 phosphorylation in human HeLa cells at 20 uM after 3 hrs by Western blotting analysis	23570615
RD	qHTS assay				qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	29435139
NB1643	qHTS assay				qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	29435139
RD	qHTS assay				qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells	29435139
SK-N-MC	qHTS assay				qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	29435139
TC32	qHTS assay				qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells	29435139
MDA-MB-231	Function assay	50 uM			Downregulation of MMP2 in human MDA-MB-231 cells at 50 uM by Western blot analysis	22926226
MDA-MB-231	Function assay	50 uM			Downregulation of MMP9 in human MDA-MB-231 cells at 50 uM by Western blot analysis	22926226
Klik om meer experimentele gegevens over cellijnen te bekijken

Chemische informatie, opslag en stabiliteit

Molecuulgewicht	267.28	Formule	C₁₆H₁₃NO₃	Opslag (vanaf de datum van ontvangst)	3 jaar-20°Cpoeder
CAS-nr.	167869-21-8	SDF downloaden		Opslag van stamoplossingen	1 jaar-80°Cin oplosmiddel 1 maand-20°Cin oplosmiddel
Synoniemen	N/A			Smiles	COC1=CC=CC(=C1N)C2=CC(=O)C3=CC=CC=C3O2

Oplosbaarheid

In vitro
Batch:

DMSO : 46 mg/mL (172.1 mM)
(Met vocht verontreinigd DMSO kan de oplosbaarheid verminderen. Gebruik verse, watervrije DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molariteitscalculator

Massa	Concentratie	Volume	Molecuulgewicht
=	×	×

Verdunningscalculator Molecuulgewichtcalculator

In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	4%DMSO 1 30%PEG300 2 5%Tween80 3 61%ddH2O Gevalideerd door Selleck labs. Mocht u aanpassingen aan deze formulering nodig hebben, neem dan contact op met ons verkoopteam voor aangepaste tests.	1.000mg/ml (3.74mM)	Taking the 1 mL working solution as an example, add 40 μL 25 mg/ml clarified DMSO stock solution to 300 μL PEG300, mix evenly to clarify it; add 50 μL Tween80 to the above system, mix evenly to clarify it; then continue to add 610 μL ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Gevalideerd door Selleck labs. Mocht u aanpassingen aan deze formulering nodig hebben, neem dan contact op met ons verkoopteam voor aangepaste tests.	1.000mg/ml (3.74mM)	Taking the 1 mL working solution as an example, add 50 μL of 20 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo formulatiecalculator (heldere oplossing)

Stap 1: Voer onderstaande informatie in (Aanbevolen: een extra dier om rekening te houden met verlies tijdens het experiment)

Dosering: mg/kg Gemiddeld gewicht van dieren: g Doseervolume per dier:μL Aantal dieren:

Stap 2: Voer de in vivo formulering in (Dit is alleen de calculator, geen formulering. Neem eerst contact met ons op als er geen in vivo formulering is in de sectie oplosbaarheid.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Berekeningsresultaten:

Werkconcentratie: mg/ml;

Methode voor het bereiden van DMSO-moedervloeistof: mg geneesmiddel vooropgelost in μL DMSO ( Concentratie moedervloeistof mg/mL, Neem eerst contact met ons op als de concentratie de DMSO-oplosbaarheid van de batch van het geneesmiddel overschrijdt. )

Methode voor het bereiden van in vivo formulering: Neem μL DMSO moedervloeistof, voeg daarna toeμL PEG300, mengen en verhelderen, daarna toevoegenμL Tween 80, mengen en verhelderen, daarna toevoegen μL ddH₂O, mengen en verhelderen.

Methode voor het bereiden van in vivo formulering: Neem μL DMSO moedervloeistof, voeg daarna toe μL Maïsolie, mengen en verhelderen.

Opmerking: 1. Zorg ervoor dat de vloeistof helder is voordat u het volgende oplosmiddel toevoegt.
2. Zorg ervoor dat u het/de oplosmiddel(en) in de juiste volgorde toevoegt. U moet ervoor zorgen dat de verkregen oplossing, bij de vorige toevoeging, een heldere oplossing is voordat u verdergaat met het toevoegen van het volgende oplosmiddel. Fysieke methoden zoals vortexen, ultrasoon of een warmwaterbad kunnen worden gebruikt om het oplossen te bevorderen.

Werkingsmechanisme

Kenmerken	Does not inhibit c-Raf phosphorylated MEK1.
Targets/IC₅₀/Ki	AhR (Cell-free assay) 1 μM MEK1 (Cell-free assay) 2 μM
In vitro	PD98059 remt ofwel basale MEK1 of een gedeeltelijk geactiveerde MEK geproduceerd door mutatie van serine op residuen 218 en 222 naar glutamaat (MEK-2E) met een IC50 van 2 μM. Deze verbinding remt de MAPK-homologen JNK en P38 niet. Het is zeer selectief tegen MEK, aangezien het een aantal andere kinase-activiteiten niet remt, waaronder Raf-kinase, cAMP-afhankelijk kinase, proteïne kinase C, v-Src, epidermale groeifactor (EGF) receptorkinase, insulinereceptorkinase, PDGF-receptorkinase en fosfatidylinositol 3-kinase. Deze remmer remt PDGF-gestimuleerde activering van MAPK en thymidine-incorporatie in 3T3-cellen met een IC50 van respectievelijk ~10 μM en ~7 μM. Het voorkomt krachtig de activering van MEK1 door Raf of MEK-kinase met een IC50 van 4 μM, en remt zwak de activering van MEK2 door Raf met een IC50 van 50 μM. Deze chemische stof remt de activering van MEK-homologen MKK4 en RK-kinase niet, die deelnemen aan stress- en interleukine-1-gestimuleerde kinasecascades in KB- en PC12-cellen, en de activering van p70 S6-kinase door insuline of epidermale groeifactor in Zwitserse 3T3-cellen. Het blokkeert volledig de zenuwgroeifactor (NGF)-geïnduceerde differentiatie van PC12-cellen zonder de cellevensvatbaarheid te beïnvloeden. Deze verbinding remt de proliferatie van RAW264.7-cellen in de kweek die RANKL bevat op een dosisafhankelijke manier, wat resulteert in een duidelijke afname van TRAP-positieve cellen.
Kinase Assay	In vitro MEK-remmende activiteit
Kinase Assay	De incorporatie van ³²P in myeline-basisch proteïne (MBP) wordt getest in aanwezigheid van glutathion S-transferase (GST) fusie-eiwitten die het 44-kDa MAPK (GST-MAPK) of het 45-kDa MEK (GST-MEK1) bevatten. Assays worden uitgevoerd in 50 μL van 50 mM Tris, pH 7.4/10 mM MgCl₂/2 mM EGTA/10 μM [γ-³²P]ATP met 10 μg GST-MEK1, 0.5 μg GST-MAPK en 40 μg MBP. Na incubatie bij 30°C gedurende 15 minuten worden de reacties gestopt door toevoeging van Laemmli SDS monsterbuffer. Gefosforyleerd MBP wordt gescheiden met SDS/10% PAGE.
In vivo	Behandeling van muizen 30 minuten voor focale cerebrale ischemie met PD98059 beschermt tegen schade, wat resulteert in een afname van het infarctvolume. Voorbehandeling met deze verbinding 30 minuten van tevoren en vervolgens samen met uurlijkse ceruleïne-injecties gedurende 3 uur verbetert significant ceruleïne-geïnduceerde acute pancreatitis op basis van pancreas natgewicht en histologie. Toediening van deze chemische stof (10 mg/kg) aan muizen 1 uur na carrageenan veroorzaakt een vermindering van alle gemeten ontstekingsparameters.
Referenties	[1] https://pubmed.ncbi.nlm.nih.gov/7644477/ [2] https://pubmed.ncbi.nlm.nih.gov/7499206/ [3] https://pubmed.ncbi.nlm.nih.gov/7775407/ [4] https://pubmed.ncbi.nlm.nih.gov/12237315/ [5] https://pubmed.ncbi.nlm.nih.gov/10536014/ [6] https://pubmed.ncbi.nlm.nih.gov/12370536/ [7] https://pubmed.ncbi.nlm.nih.gov/20074457/ [8] https://pubmed.ncbi.nlm.nih.gov/11254111/ [9] https://pubmed.ncbi.nlm.nih.gov/17161815/ [10] https://pubmed.ncbi.nlm.nih.gov/14506750/ [11] https://pubmed.ncbi.nlm.nih.gov/14506750/ [12] https://pubmed.ncbi.nlm.nih.gov/9495809/

Toepassingen

Methoden	Biomarkers	Afbeeldingen	PMID
Western blot	c-Jun / α-tubulin / p-ERK / ERK / p-AKT / AKT p-JNK / JNK / Cyclin D1 p-HER2 / HER2 MMP9 / XIAP / VEGF		17482134

Technische ondersteuning

Gebruiksaanwijzing

Tel: +1-832-582-8158 Ext:3

Als u nog andere vragen heeft, laat dan een bericht achter.

Veelgestelde vragen

Vraag 1:
How to formulate this inhibitor for i.p. injection?

Antwoord:
You can prepare the stock of this compound by the vehicle 30% PEG400/0.5% Tween80/5% Propylene glycol, 0.5% CMC.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):